Drug Trial Radar · NCT06921785
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
Last checked: Nov 20, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,220
Planned (sponsor's estimate)
Start
May 6, 2025
Primary completion
Mar 15, 2030
Study completion Mar 15, 2030
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Apr 10, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase III, randomised, open-label, sponsor-blinded, 3-arm, multicentre, global study assessing the efficacy and safety of rilvegostomig in combination with bevacizumab with or without tremelimumab compared to atezolizumab in combination with bevacizumab. This study will be conducted in participants with advanced HCC who are not amenable to curative therapy or locoregional therapy
Conditions
- Hepatocellular Carcinoma
Interventions
TremelimumabDrug
IV therapy
RilvegostomigDrug
IV therapy
BevacizumabDrug
IV therapy
AtezolizumabDrug
IV therapy
Primary outcomes
What the sponsor says the trial is designed to measure.
- To demonstrate the efficacy of Arm A relative to Arm C by assessment of OS in participants with advanced HCCTime frame: Up to approximately 6 years
Locations
226 sites in 20 countries. Site status is shown where the registry gives one.
Research Site
Phoenix, Arizona · Recruiting
Research Site
Tucson, Arizona · Recruiting
Research Site
Los Angeles, California · Recruiting
Research Site
Palo Alto, California · Recruiting
Research Site
Denver, Colorado · Not yet recruiting
Research Site
New Haven, Connecticut · Recruiting
Research Site
Newark, Delaware · Recruiting
Research Site
Jacksonville, Florida · Recruiting
Research Site
Orlando, Florida · Not yet recruiting
Research Site
Atlanta, Georgia · Recruiting
Research Site
Atlanta, Georgia · Withdrawn
Research Site
Honolulu, Hawaii · Withdrawn
Research Site
Chicago, Illinois · Recruiting
Research Site
Indianapolis, Indiana · Not yet recruiting
Research Site
Shreveport, Louisiana · Not yet recruiting
Research Site
Detroit, Michigan · Recruiting
Research Site
Grand Rapids, Michigan · Recruiting
Research Site
Rochester, Minnesota · Recruiting
Research Site
St Louis, Missouri · Not yet recruiting
Research Site
New Brunswick, New Jersey · Recruiting
Research Site
New York, New York · Recruiting
Research Site
New York, New York · Recruiting
Research Site
New York, New York · Not yet recruiting
Research Site
Cleveland, Ohio · Withdrawn
Research Site
Oklahoma City, Oklahoma · Not yet recruiting
Research Site
Philadelphia, Pennsylvania · Not yet recruiting
Research Site
Pittsburgh, Pennsylvania · Recruiting
Research Site
Amarillo, Texas · Recruiting
Research Site
Austin, Texas · Recruiting
Research Site
Dallas, Texas · Withdrawn
Research Site
Houston, Texas · Recruiting
Research Site
San Antonio, Texas · Recruiting
Research Site
Tyler, Texas · Recruiting
Research Site
Arlington, Virginia · Recruiting
Research Site
Salem, Virginia · Recruiting
Research Site
Seattle, Washington · Recruiting
Research Site
Milwaukee, Wisconsin · Recruiting
Research Site
Camperdown, Australia · Recruiting
Research Site
Clayton, Australia · Recruiting
Research Site
Heidelberg, Australia · Recruiting
Showing 40 of 226 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.